

# Anti-cancer inhibitor could have dual effect

October 22 2021, by Will Doss




Figure 1. Tissue transglutaminase (TG2) promotes peritoneal tumor growth in a syngeneic ovarian cancer (OC) mouse model by preventing CD8<sup>+</sup> T cell infiltration into ascites. (A, B) Volume of peritoneal ascites (mean±SEM, n=23 per group, cumulative data from four independent experiments are shown) (A), and numbers of cells in ascites (mean±SEM, n=5 per group, data from one representative experiment out of two performed are shown) (B) in C57BL/6 (TG2<sup>+/+</sup>) and TG2 knockout (TG2<sup>-/-</sup>) female mice 6 weeks after intraperitoneal

injection of ID8 cells. Shown are t-test p values. (C) Images of peritoneal metastases in TG2+/+ and TG2-/- abdominal cavities. Tumor implants are indicated by blue arrows. (D) Kaplan-Meier survival analysis of TG2+/+ (n=12) and TG2-/- (n=14) mice injected intraperitoneally with ID8 cells. Graph represents data from one experiment out of two performed. (E–H) Measurements by flow cytometry of percentages of immune cells in TG2+/+ and TG2-/- mice-bearing tumors induced by intraperitoneal inoculation of ID8 cells. (E) CD8+ and CD4+ T cells in spleens (TG2+/+, n=10; TG2-/-, n=9; data from two experiments). (F) CD8+ and CD4+ T cells in abdominal ascites (TG2+/+, n=13; TG2-/-, n=16; data from four experiments). (E, F) Programmed cell death protein 1 (PD-1) expressing CD8+ T cells in spleen (n=7 per group; data from one representative experiment) and ascites (n=9 per group; data pooled from three experiments). Values are means  $\pm$  SEM (\*p

Citation: Anti-cancer inhibitor could have dual effect (2021, October 22) retrieved 25 April 2024 from <https://medicalxpress.com/news/2021-10-anti-cancer-inhibitor-dual-effect.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.